Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox
 


  UK's vaccination campaign

The United Kingdom’s Meningitis C Vaccination Program

The incidence of meningococcal disease in England and Wales has increased significantly over the last five years; with the proportion due to serogroup C rising from 16% to 40% of laboratory confirmed cases. The Meningitis C Immunization Program was initiated in November 1999 in order to provide new meningococcal C conjugate vaccine to everyone in the UK under the age of 18. The UK was the first country worldwide to license and market this new kind of vaccine. The first phase of the campaign included vaccination of children aged 15 to 17 years and infants at the age of 2 , 3 , 4 and 13 months. The second phase included infants aged 5 to 12 months and children aged 5 to 14 years.
As a result, cases of meningitis C have dropped dramatically over six months following the campaign. The number of cases of the disease decreased by 90% for children under 1, and 15 to 17 years of age. Across all children under the age of 18, meningitis C dropped by 75%. It is estimated that 500 cases of meningitis C and septicemia and 50 deaths have been prevented in this period of time. (6,7,26-32)


 » Printversion

 
 
  » find


 

Baxter initiates clinical study with cell-based candidate H5N1 Pandemic Vaccine
» read more

Baxter to participate in development of cell-based vaccines for U.S. Department of Health and Human Services
» read more

Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,